Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cedars, Ari
FonDap, NCT05741658: The Fontan Dapagliflozin Pilot Study	Enrolling by invitation	4	29	US	Dapagliflozin 10mg Tab	Johns Hopkins University, University of California, Los Angeles, Brett Boyer Foundation, AstraZeneca	Heart Failure	07/25	08/25
Zeisset, Kaitlynn
EQUATE, NCT03763318: A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD	Completed	1b/2	30	US	EQ001, Bmab600, Itolizumab, EQ001 Placebo	Equillium, Biocon Limited	Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute	11/22	11/22
NCT06126003: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.	Terminated	N/A	2	US	Observation	BioCorteX Inc, Tempus AI	Breast Cancer	07/24	07/24
NCT06207032: TEMPUS ARIES: A Biobank Registry Platform Study in Oncology	Recruiting	N/A	500	US		Tempus AI	Cancer	06/29	06/29
NCT06163534: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)	Recruiting	N/A	500	US		Tempus AI, AstraZeneca	Head and Neck Squamous Cell Carcinoma	03/28	03/28